Skip to content
MXCT·Nasdaq·US

MaxCyte

MaxCyte provides cell-engineering and electroporation technologies used by biotechnology and cell-therapy developers to modify cells for research and therapeutic manufacturing. The company monetizes its platforms through instruments, consumables, and technology licensing to life-science customers.

Recent Activity

Updated Sep 24, 2026
–MaxCyte appointed Sidharth Kapileshwar as Chief Corporate Development Officer.

Past updates are part of the Pro plan.

Thematic Position

MXCT

Relationship Groups

Customers2
Licensing1
Competitors3

Relationship details are part of the Pro plan.

Ended Relationships

4 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

tarifftrade restriction
U.S. tariffs on China, Canada, Mexico, India imports affecting sales and costs
SEC 10-KMar 25, 2026

The full regulatory passage is part of the Pro plan.

5 more · Regulatory and geopolitical insights are part of the Pro plan.